Sahajanand Medical Technologies IPO GMP Today

Sahajanand Medical Technologies Limited develops, manufactures, and sells medical devices used in vascular and structural heart interventions. Founded in 2001, the company offers vascular intervention products, including coronary stents and coronary balloon catheters, and structural heart products, including transcatheter aortic valve implantation (TAVI) devices and occluders. Its portfolio also includes renal stents, peripheral drug-coated balloons, and traded medical products. The company markets its products through direct sales, hybrid, and distributor-led models. In FY26, it generated revenue from 77 countries, including India, with operations across Europe and other international markets. It currently operates three manufacturing facilities, two in India and one in Thailand. Additionally, it has two research and development centres, located in India and Thailand, focused on medical device development and product improvements. Use of proceeds: The IPO is an offer-for-sale (OFS). The company will not receive any proceeds from the offer. Net proceeds from the offer will go to the promoter selling shareholders in proportion to the number of shares offered by them for sale. The primary objective of the offer is to achieve the benefits of listing the equity shares on the stock exchanges, which is expected to enhance the company’s visibility and brand recognition. Listing will also provide liquidity to the existing shareholders and create a public market for the company’s shares in India​.